左西孟旦应用于机体重要器官疾病的研究进展

doi:10.3969/j.issn.1004-583X.2023.06.018

摘要/Abstract

摘要：

左西孟旦目前广泛应用于心血管疾病领域,近年研究发现除改善心功能外还具有保护肾脏、肝脏,改善再灌注损伤及肠道微循环障碍等其他作用。为更好地了解该药在不同疾病中的应用情况,本文就目前国内外收录的左西孟旦临床应用相关文献进行归纳与总结,以期为该药的临床新应用提供参考。

关键词: 心力衰竭, 肾功能不全, 微循环, 左西孟旦

中图分类号:

R541.6

于晓东, 任晓艺, 刘美霞. 左西孟旦应用于机体重要器官疾病的研究进展[J]. 临床荟萃, 2023, 38(6): 573-576.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.06.018

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I6/573

参考文献 30

[1]	Yamamoto S, Yamamoto M, Nakamura J, et al. Spatiotemporal ATP dynamics during AKI predict renal prognosis[J]. J Am Soc Nephrol, 2020, 31(12):2855-2869. doi: 10.1681/ASN.2020050580 pmid: 33046532
[2]	Krychtiuk KA, Kaun C, Hohensinner PJ, et al. Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro[J]. Vascul Pharmacol, 2017, 90:44-50. doi: 10.1016/j.vph.2017.02.003 URL
[3]	潘莉, 陈旭红. 左西孟旦对右心室衰竭大鼠右心功能、心肌能量代谢和心肌代谢的影响[J]. 中国医院药学杂志, 2018, 38(15):1590-1594.
[4]	Lyhne MD, Dragsbaek SJ, Hansen JV, et al. Levosimendan, milrinone, and dobutamine in experimental acute pulmonary embolism[J]. Pulm Circ, 2021, 11(3):20458940211022977.
[5]	汪雁博, 郝国贞, 姜云发, 等. 左西孟旦对急性失代偿性心力衰竭患者右心功能的影响研究[J]. 中国全科医学, 2019, 22(27):3328-3332. doi: 10.12114/j.issn.1007-9572.2019.00.301
[6]	赵文思. 左西孟旦对右心功能的影响[D]. 湖南: 南华大学, 2020.
[7]	Abdelrahman AM, AI Salam S, AI Sulemani Y, et al. Effect of levosimendan, an inodilator, on streptozotocin-induced diabetic nephropathy in rats[J]. Eur J Pharmacol, 2020, 873:172960. doi: 10.1016/j.ejphar.2020.172960 URL
[8]	Tian L, Wang S, Zhao L, et al. Renoprotective effects of levosimendan on acute kidney injury following cardiac arrest via anti-inflammation, anti-apoptosis and ERK activation[J]. FEBS Open Bio, 2021, 11(8):2236-2244. doi: 10.1002/2211-5463.13227 pmid: 34115930
[9]	Guerrero-Orriach JL, Malo-Manso A, Ramirez-Aliaga M, et al. Renal and neurologic benefit of levosimendan vs dobutamine in patients with low cardiac output syndrome after cardiac surgery: Clinical trial FIM-BGC-2014-01[J]. Front Pharmacol, 2020, 11:1331. doi: 10.3389/fphar.2020.01331 pmid: 32982742
[10]	周程辉, 龚俊松, 刘斌. 左西孟旦对左心功能不全心脏病患者围术期肾保护作用的系统评价与Meta分析[J]. 中国胸心血管外科临床杂志, 2019, 26(5):470-479.
[11]	魏望江, 曾志立, 吴其明. 左西孟旦对心力衰竭患者心肾功能影响的meta分析[J]. 世界临床药物, 2021, 42(3):181-187.
[12]	Long YX, Cui DY, Kuang X, et al. Effect of levosimendan on renal function in background of left ventricular dysfunction: A meta-analysis of randomized trials[J]. Expert Opin Drug Saf, 2021, 20(11) : 1411-1420. doi: 10.1080/14740338.2021.1951700 URL
[13]	Hein M, Zoremba N, Bleilevens C, et al. Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model[J]. BMC Neurol, 2013, 13:106. doi: 10.1186/1471-2377-13-106 pmid: 23937651
[14]	Plaschke K, Bent F, Wagner S, et al. In contrast to its anti-inflammatory and anti-apoptotic peripheral effect, levosimendan failed to induce a long-term neuroprotective effect in a rat model of mild septic encephalopathy: A pilot study[J]. Neurosci Lett, 2014, 560:117-121. doi: 10.1016/j.neulet.2013.12.021 pmid: 24361133
[15]	García-Bardon A, Kamuf J, Ziebart A, et al. Levosimendan increases brain tissue oxygen levels after cardiopulmonary resuscitation independent of cardiac function and cerebral perfusion[J]. Sci Rep, 2021, 11(1): 14220. doi: 10.1038/s41598-021-93621-x pmid: 34244561
[16]	Grossini E, Bellofatto K, Farruggio S, et al. Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay[J]. PLoS One, 2015, 10(4):e0124742. doi: 10.1371/journal.pone.0124742 URL
[17]	Sakaguchi T, Hashimoto Y, Matsushima H, et al. Levosimendan pretreatment improves survival of septic rats after partial hepatectomy and suppresses iNOS induction in cytokine-stimulated hepatocytes.[J]. Sci Rep, 2019, 9(1):13398. doi: 10.1038/s41598-019-48792-z pmid: 31527618
[18]	Grossini E, Pollesello P, Bellofatto K, et al. Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats[J]. Liver Transpl, 2014, 20(3):361-375. doi: 10.1002/lt.23799 URL
[19]	Suakıtıcı S, Güven BB, Tanoglu A, et al. A combination of levosimendan and N-Acetylcysteine shows significant favorable efficacy on experimental liver ischemia/reperfusion injury[J]. Ulus Travma Acil Cerrahi Derg, 2021, 27(4):381-388. doi: 10.14744/tjtes.2020.81782 pmid: 34213003
[20]	杨飞, 王少华, 赵丽娜, 等. 静脉注射左西孟旦治疗晚期严重心力衰竭患者的疗效分析[J]. 中国急救医学, 2018, 38(8):706-710.
[21]	Zemljic G, Anzic DA, Cerar A, et al. Abstract 15719: Levosimendan improves liver function in patients with advanced chronic heart failure[J]. Circulation, 2020, 142(Suppl_3): A15719.
[22]	梅松, 蒋雯, 白向锋, 等. 左西孟旦治疗重症冠心病所致心衰的临床疗效[J]. 昆明医科大学学报, 2021, 42(1):72-75.
[23]	王世伟, 郭建, 杨正飞, 等. 左西孟旦对心肺复苏后大鼠肠道微循环的影响[J]. 临床急诊杂志, 2019, 20(8):612-618.
[24]	Boost KA, Hoegl S, Dolfen A, et al. Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury[J]. Crit Care Med, 2008, 36(6):1873-1879. doi: 10.1097/CCM.0b013e3181743e63 pmid: 18496375
[25]	Gürbüzel M, Sayar I, Cankaya M, et al. The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats[J]. Pharmacol Rep, 2016, 68(2):378-382. doi: 10.1016/j.pharep.2015.10.001 pmid: 26922542
[26]	Fodor GH, Bayat S, Babik B, et al. Reversing cholinergic bronchoconstriction by common inotropic agents: A randomized experimental trial on isolated perfused rat lungs[J]. Anesth Analg, 2019, 129(3):745-752. doi: 10.1213/ANE.0000000000003502 pmid: 31425216
[27]	Rieg AD, Suleiman S, Bünting NA, et al. Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels[J]. PLoS One, 2020, 15(5): e0233176. doi: 10.1371/journal.pone.0233176 URL
[28]	欧伟根, 蔡洪流. 左西孟旦注射液治疗慢性阻塞性肺疾病伴心功能不全的临床研究[J]. 中国临床药理学杂志, 2017, 33(16):1527-1530.
[29]	梅姜. 左西孟旦对困难脱机病人的临床疗效观察[D]. 北京: 北京协和医学院, 2019.
[30]	黄奎, 温小琴, 任宁, 等. 左西孟旦在急性呼吸衰竭合并心力衰竭患者二次脱离机械通气中的应用[J]. 山东医药, 2020, 60(23):48-50.

左西孟旦应用于机体重要器官疾病的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	储丽清, 杨敏. 运动疗法在慢性肾脏病中的应用进展[J]. 临床荟萃, 2024, 39(2): 183-187.
[2]	马丽娜, 焦焕利, 曹振华. 慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展[J]. 临床荟萃, 2024, 39(1): 75-79.
[3]	段芳, 崔炜. 血管扩张剂在急性心力衰竭救治中的应用原则[J]. 临床荟萃, 2023, 38(9): 773-778.
[4]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[5]	尚蒙, 王礼琳. 沙库巴曲/缬沙坦对慢性心力衰竭患者心律失常影响的研究进展[J]. 临床荟萃, 2023, 38(5): 459-464.
[6]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[7]	王凤华, 魏茂提. 干式桑拿疗法治疗慢性心力衰竭的研究进展[J]. 临床荟萃, 2023, 38(4): 369-372.
[8]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[9]	李娜娜, 江珊. 血清同型半胱氨酸、胱抑素C、超敏C-反应蛋白水平对急性ST段抬高型心肌梗死患者PCI术后并发心力衰竭的预测价值[J]. 临床荟萃, 2023, 38(2): 121-125.
[10]	董慧, 黄文辉, 赵慧, 钱睿. 成人Bartter综合征合并慢性肾功能不全急性加重1例[J]. 临床荟萃, 2023, 38(11): 1022-1026.
[11]	刘向东, 蔡延东, 秦延军, 李云松, 李亮, 高瑞姣, 任磊, 张彦荣. 运动性横纹肌溶解症并发急性肾功能不全及透析管相关性血栓1例并文献复习[J]. 临床荟萃, 2022, 37(9): 831-833.
[12]	邓媛媛, 岑梅, 金铭, 赵丽静, 张旖旎, 张智香. 慢性心力衰竭合并低蛋白血症患者营养管理的研究进展[J]. 临床荟萃, 2022, 37(9): 838-841.
[13]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[14]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.
[15]	张宏涛, 杨雨, 王志奎. 腹膜透析患者心力衰竭治疗药物研究进展[J]. 临床荟萃, 2022, 37(6): 556-559.